에 대한 최신 뉴스 Akero Therapeutics (NASDAQ:AKRO) 주식

Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Inc

Akropolis

Raymond James analyst Steve Moss reiterates Chain Bridge Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBNA#NYSE">CBNA</a>) with a Strong Buy and raises the price target from $29 to $34.

News

Price Target

Reiteration

Analyst Ratings

CBNA

Raymond James Reiterates Strong Buy on Chain Bridge Bancorp, Raises Price Target to $34

ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>), a leading provider of IT services and professional solutions across the commercial and government sectors, announced today that ASGN President Rand Blazer (75) will transition to the role of Executive Vice Chairman on March 1, 2025. As part of a planned succession, Shiv Iyer, former Americas Consulting and Industry X Lead Executive for Accenture, will become President and join the executive team.
 &nbsp;

Management

ASGN

ASGN Announces President Rand Blazer Will Transition To The Role Of Executive Vice Chairman On March 1, 2025; Shiv Iyer Will Become President And Join The Executive Team As Part Of Succession Plan

The <a href="https://www.benzinga.com/topic/artificial-intelligence">AI-driven market</a> surge has hit troubled times and JPMorgan analyst Jason Hunter is telling investors to be cautious.
Recent bear gaps in AI stocks have cracked short-term trend support, leaving tech darlings like Nvidia Corp (NVDA), Broadcom Inc (AVGO) and Marvell Technology Inc (MRVL) looking vulnerable. 
But before VOO investors start sweating, there&#8217;s a silver lining: the broader market, and by extension the Vanguard S&amp;P 500 ETF (VOO), remains well-anchored.
<h2 class="wp-block-heading">AI's Stumble Vs. The Broader Market Picture</h2>
Tech stocks have been leading the charge, and their weight in the S&amp;P 500—over 37% of VOO's holdings—means any AI sector shake-up has ripple effects. 
NVDA stock, for instance, is fighting to hold key support near $114, while AVGO stock eyes a rebound from the $180-$186 range, per Hunter. The iShares Semiconductor ETF (SOXX), a key barometer for AI and chip stocks, has lost 7.54% in just five days. While that signals near-term pain, Hunter points out that longer-term support levels remain intact.
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43291968/3-etfs-shine-as-trumps-first-week-sparks-record-gains-followed-by-tech-slump">3 ETFs Shine As Trump&#8217;s First Week Sparks Record Gains Followed By Tech Slump</a>
<h2 class="wp-block-heading">What This Means For VOO Investors</h2>
VOO, a favorite among passive investors, is designed for broad-market exposure. Unlike concentrated tech plays, it absorbs volatility better thanks to diversification. Microsoft Corp (MSFT), Apple Inc (AAPL) and Amazon.com Inc (AMZN) may feel the tech squeeze, but financials, healthcare and consumer staples act as stabilizers.
JPMorgan's take? While AI stocks may struggle to regain immediate footing, they're approaching key support levels, likely forming a multi-week or multi-month trading range rather than a prolonged downturn.
<h2 class="wp-block-heading">Stay The Course Or Shift Gears?</h2>
Short-term traders might see this as an opportunity to hedge, but for long-term VOO investors, the playbook remains unchanged: stay the course. 
VOO's resilience comes from its balanced exposure to 500 of the biggest U.S. companies, smoothing out sector-specific dips. If AI rebounds as expected, VOO holders will benefit without needing to time the market.
The bottom line? 
AI may be wobbling, but VOO investors have little reason to panic. The ETF's broad-market strategy keeps it on solid ground, making short-term volatility a mere blip in the bigger picture.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43142623/happy-birthday-sp-500-spy-etf-if-you-invested-1000-in-spy-at-launch-heres-how-much-youd-have-today">Happy Birthday S&amp;P 500 SPY ETF! If You Invested $1,000 In SPY At Launch, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
Photo Shutterstock

Analyst Color

Long Ideas

Technicals

Tech

Trading Ideas

AAPL

AMZN

AVGO

MRVL

MSFT

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Why VOO Investors Should Keep Calm Despite AI Stock Turbulence

JMP Securities analyst Nicholas Jones reiterates Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Market Outperform and maintains $285 price target.

JMP Securities Reiterates Market Outperform on Amazon.com, Maintains $285 Price Target

Mixed Martial Arts Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) ("MMA.inc" or the "Company"), a leading technology company building the commercial and cultural epicenter for the mixed martial arts (MMA) and combat sports industry, is accelerating its customer growth strategy in readiness for the upcoming integration of BJJLink, a premier digital platform tailored for Brazilian Jiu Jitsu and martial arts academies, into MixedMartialArts.com.&nbsp;
We believe this strategic alignment creates the most advanced gym management, community engagement, and monetization ecosystem in combat sports, fueling subscription-based and transaction fee revenue growth for MMA.inc and unlocking new opportunities for gym owners, coaches, and athletes worldwide.

Mixed Martial Arts Group Acquisition Of BJJLink Helps Fuel +40% YOY Revenue Growth On The Platform As It Targets 44,000 Gyms In The Martial Arts Industry In The U.S.

Raymond James analyst David Hicks maintains C.H. Robinson Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) with a Outperform and lowers the price target from $123 to $118.

CHRW

Raymond James Maintains Outperform on C.H. Robinson Worldwide, Lowers Price Target to $118

Wells Fargo analyst Joe Quatrochi maintains MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Equal-Weight and raises the price target from $19 to $20.

Wells Fargo Maintains Equal-Weight on MaxLinear, Raises Price Target to $20

Guidance

SNDR

Schneider National Sees FY25 Adj EPS Of  $0.90 - $1.20 Vs. $1.1 Est.

Nokia Corp (NYSE: NOK) reported <a href="https://www.benzinga.com/topic/nokia" target="_blank" rel="noopener">fiscal fourth-quarter</a> net sales growth of 10% year-on-year to 5.98 billion euros ($6.39 billion), beating the <a href="https://www.nokia.com/about-us/investors/results-reports/" target="_blank" rel="noopener">analyst consensus estimate of $6.17 billion</a>. 
This reflects a strong recovery in demand from communication service providers, notably in North America. Nokia expects the trend to persist in 2025.
The comparable EPS was 19 cents (0.15 euros), compared to the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate of 13 cents</a>. 
The reported net income is 813 million euros, up from a loss of 33 million euros a year ago.
Also Read: <a href="https://www.benzinga.com/25/01/43306451/taiwan-semiconductor-gains-government-support-faces-trumps-tariff-threats-in-us-trade-battle" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Gains Government Support, Faces Trump&#8217;s Tariff Threats, Cheaper Chinese Rivals</a>
Comparable net profit was 977 million euros, up from 555 million euros a year earlier.
Network Infrastructure sales increased by 17% year over year in CC with growth in all business divisions. Cloud and Network Services sales increased by 7% year over year in CC&nbsp;&nbsp;driven by strength in both Core Networks and Enterprise Campus Edge.
Nokia Tech sales climbed by 85% year over year in CC, due to catch-up payments and also a higher net sales run-rate from deals signed in the quarter along with previously signed smartphone license agreement renewals.
Mobile Network sales declined by 2% year over year in CC, driven by APAC, while both Americas and EMEA grew.
Margins: Gross margin climbed by 280 bps to 46.1%. The comparable gross margin improved by 250 bps to 47.2% with a strong contribution from Nokia Technologies.
The operating margin increased by 540 bps to 15.3%, and the comparable operating margin improved by 380 bps to 19.1%, mainly due to higher gross margin and continued cost control.
In the quarter, Nokia&nbsp;held 4.9 billion euros in net cash and generated 0.05 billion euros in free cash flow.
Dividend: The board proposed a dividend authorization of 0.14 euros per share.
FY25 Outlook:&nbsp;Nokia&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">expects a&nbsp;comparable operating profit</a>&nbsp;of 1.9 billion euros-2.4 billion euros and free cash flow conversion from a comparable operating profit of 50%-80%.
Nokia stock surged 21% in the last 12 months. Investors can gain exposure to the stock through Defiance Quantum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTUM#NASDAQ">QTUM</a>) and Defiance Connective Technologies ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIXG#NASDAQ">SIXG</a>).
Price Action:&nbsp;NOK stock is up 4.28% at $4.63 premarket at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43311376/alibaba-ups-ai-game-says-its-qwen2-5-max-beats-deepseek-and-openai-in-performance" target="_blank" rel="noreferrer noopener">Alibaba Ups AI Game, Says Its Qwen2.5 Max Beats DeepSeek and OpenAI In Performance</a></li>
</ul>
Image: Courtesy of Nokia

Earnings

Dividends

QTUM

SIXG

Nokia Beats Q4 Earnings Estimates Thanks To Strong Infrastructure, Proposes Dividend Increase

Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) announced its Q4 earnings on Thursday, January 30, 2025 at 09:00 AM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Schneider National missed estimated earnings by 0.0%, reporting an EPS of $0.2 versus an estimate of $0.2.
Revenue was down $33.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
In the previous quarter, the company missed on EPS by $0.05, resulting in a 0.0% increase change in the share price the following day.
Here's a look at Schneider National's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.18</td>
<td>0.12</td>
<td>0.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.18</td>
<td>0.21</td>
<td>0.11</td>
<td>0.16</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.33B</td>
<td>1.35B</td>
<td>1.36B</td>
<td>1.35B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.32B</td>
<td>1.32B</td>
<td>1.32B</td>
<td>1.37B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Schneider National management provided guidance for FY 2025, expecting earnings between $0.9 and $1.2 per share.
To track all earnings releases for Schneider National <a href="https://www.benzinga.com/quote/SNDR/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Schneider National Q4 Earnings Assessment

Raymond James analyst Sam Darkatsh reiterates Applied Industrial Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) with a Outperform and raises the price target from $250 to $265.

Raymond James Reiterates Outperform on Applied Industrial Techs, Raises Price Target to $265

Keybanc analyst Aleksey Yefremov reiterates Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and maintains $750 price target.

Keybanc Reiterates Overweight on Meta Platforms, Maintains $750 Price Target

Safe and Green Development Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGD#NASDAQ">SGD</a>) ("SGD" or the "Company") today announced the resolution of certain inter-company financial obligations with Safe &amp; Green Holdings Corp. (SGBX).
Under the terms of the agreement, SGD has forgiven and released SGBX from obligations under a promissory note dated August 9, 2023, with a principal amount of $908,322.95 and intercompany advances of $815,522 (which SGD had previously written off its balance sheet as of 12.31.23) in exchange for SGBX forgiving $394,329 of inter-company debt owed to SGBX by SGD and for SGBX transferring 276,425 shares of SGD Common Stock owned by SGBX to SGD. SGD currently plans to hold such shares in its treasury. As a result of this agreement, SGBX will no longer be a stockholder of SGD.

Financing

Legal

SGBX

Safe And Green Development Resolves Financial Obligations With Safe & Green Holdings; Forgives $908K Debt, Offsets $815K Advances; SGBX Forgives $394K Debt, Transfers 276K SGD Shares To Treasury; SGBX Ceases To Be SGD Stockholder

Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) reported quarterly adjusted earnings of $0.20 per share which met the analyst consensus estimate. This is a 25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $1.34 billion which missed the analyst consensus estimate of $1.36 billion by 1.69 percent. This is a 2.41 percent decrease over sales of $1.37 billion the same period last year.

Earnings Misses

Schneider National Q4 Adj $0.20, Inline, Sales $1.34B Miss $1.36B Estimate

Panama President Mulino Rules Out Discussing Issue of Control of Panama Canal In Meeting With Us Secretary Of State Rubio This Weekend

Buybacks

Cullen/Frost Bankers Board Authorizes $150M Buyback Program

Raymond James analyst David Long reiterates Alerus Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) with a Outperform and raises the price target from $22 to $24.

ALRS

Raymond James Reiterates Outperform on Alerus Finl, Raises Price Target to $24

Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported weaker-than-expected fourth-quarter <a href="https://www.benzinga.com/quote/dhr/earnings">earnings on Wednesday</a>.
The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.
The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.
Rainer M. Blair, President and Chief Executive Officer, stated, "Good execution by our team also drove solid cash flow and operating margin expansion."
Danaher said it expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter. However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.
Danaher shares fell 9.7% to close at $223.73 on Wednesday.
These analysts made changes to their price targets on Danaher following earnings announcement.
<ul>
<li>Barclays analyst Luke Sergott maintained Danaher with an Equal-Weight and lowered the price target from $275 to $240.</li>
<li>Wells Fargo analyst Brandon Couillard maintained Danaher with an Equal-Weight and cut the price target from $280 to $240.</li>
</ul>
Considering buying DHR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-1024x578.png" alt="" class="wp-image-758143" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30090148/image-261.png 1120w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a></li>
</ul>

Markets

Danaher Analysts Cut Their Forecasts After Downbeat Earnings

Fixed income investors are finally seeing some relief after enduring the longest <a href="https://www.benzinga.com/topic/yield-curve">yield curve inversion</a> in modern history. 
<h2 class="wp-block-heading">Yield Curve Steepening: A Shift After Years Of Inversion</h2>
Since July 2022, short-term yields sat stubbornly above long-term yields, creating a highly unusual environment. But as of December 2024, the yield curve has returned to positive territory, though it remains far from its historical norm. 
The 2-year/10-year spread now sits at just +0.33%, well below the 1% average.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/01/43059174/buy-long-duration-bonds-says-bank-of-america-strategist">&#8216;Buy Long Duration Bonds,&#8217; Says Bank Of America Strategist: 4 ETFs To Watch As Trump&#8217;s Deficit Fight Unfolds</a>
<h2 class="wp-block-heading">Where The Best Value Lies In Corporate Bonds</h2>
According to Lawrence Gillum, Chief Fixed Income Strategist at LPL Financial, the Treasury curve may continue to steepen as:
<ul>
<li>economic data beats expectations, </li>
<li>inflation remains sticky</li>
<li>Treasury issuance ramps up to cover widening budget deficits. </li>
</ul>
However, despite this shift, Gillum believes the best &#8220;bang for your buck&#8221; still lies in the 1–5-year segment of the corporate credit curve, with the 5–7-year range also offering incremental value.
<h2 class="wp-block-heading">ETFs To Capitalize On The Opportunity</h2>
For investors looking to position themselves accordingly, ETFs like the iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LQD#NYSE">LQD</a>) and the SPDR Portfolio Corporate Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPBO#NYSE">SPBO</a>) provide broad exposure to investment-grade corporate credit. Meanwhile, those wanting to stay on the shorter end can consider the Vanguard Short-Term Corporate Bond ETF (VCSH) or the iShares 1-5 Year Investment Grade Corporate Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGSB#NASDAQ">IGSB</a>), both of which align with Gillum's recommended maturity range.
The takeaway? While longer-term yields are climbing, short- to intermediate-term corporate bonds currently present a compelling risk-reward tradeoff. Some investors are looking to lock in yields while the opportunity remains.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43101541/exclusive-powell-co-will-wait-wisdomtree-expert-says-on-why-investors-need-smarter-bond-strategy" target="_blank" rel="noreferrer noopener">EXCLUSIVE: &#8216;Powell &amp; Co. Will Wait&#8217; — WisdomTree Expert On Why Investors Need Smarter Bond Strategy</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Bonds

Broad U.S. Equity ETFs

Specialty ETFs

ETFs

IGSB

SPBO

VCSH

'Best Bang For Your Buck': Expert Sees Strongest Value In 1–5 Year Credit Curve

Keybanc analyst Alex Markgraff maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Overweight and raises the price target from $50 to $57.

HOOD

Keybanc Maintains Overweight on Robinhood Markets, Raises Price Target to $57

Analyst David Lebowitz of Citi maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $65.00. David Lebowit...

Akero Therapeutics' Efruxifermin Shows Promise: Buy Rating Backed by Upcoming SYMMETRY Data and Potential Stock Upside

Morgan Stanley raised the firm's price target on Akero Therapeutics (AKRO) to $96 from $46 and keeps an Overweight rating on the shares after 96-we...

Akero Therapeutics price target raised to $96 from $46 at Morgan Stanley

Jonathan Woo, an analyst from Phillip Securities, maintained the Buy rating on Akero Therapeutics (AKRO – Research Report). The associated price ta...

Akero Therapeutics: Promising SYMMETRY Trial Results Position Efruxifermin for Market Success

Some Good MASH/NASH News From Akero Therapeutics

Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients

Akero Therapeutic prices upsized stock offering of $350M

The deal size was raised to $350M in common stock from $300M in common stock. JPMorgan, Morgan Stanley and Jefferies acted as joint book running ma...

Akero Therapeutics 5.333M share Secondary priced at $48.00

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

89bio's Pegozafermin Is Now Gaining Momentum

As previously reported, BofA upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a price target of $63, up from $35. Akero's 96-week update...

Akero upgraded to Buy at BofA after 'transformative' liver data

AKRO

ALLK

ETNB

MDGL

NONOF

ONCO

TVGN

VKTX

Press Releases

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Health Care

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

General

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Comments

Akero Therapeutics

뉴스

에 대한 최신 뉴스 Akero Therapeutics (NASDAQ:AKRO) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌